Cosentyx is a biologic medication used to treat autoimmune disorders such as psoriasis and psoriatic arthritis. The active ingredient in Cosentyx is secukinumab, which is a monoclonal antibody that targets interleukin-17A, a protein that plays a key role in the development of autoimmune diseases [1].

According to a study published in the Journal of Clinical Medicine, monitoring the levels of Cosentyx in the blood can help determine the effectiveness of treatment and the potential for adverse effects [2]. The study found that patients who had higher levels of Cosentyx in their blood had better clinical outcomes, such as reduced skin inflammation and joint pain. Additionally, patients with higher levels of Cosentyx were less likely to experience adverse effects, such as infections or injection site reactions.

Another study published in the Journal of Dermatological Treatment found that patients who received higher doses of Cosentyx had better clinical outcomes than those who received lower doses [3]. The study concluded that higher doses of Cosentyx may be necessary to achieve optimal clinical outcomes in patients with psoriasis.

In summary, monitoring the levels of Cosentyx in the blood can help determine the effectiveness of treatment and the potential for adverse effects. Higher levels of Cosentyx are associated with better clinical outcomes and a lower risk of adverse effects. Additionally, higher doses of Cosentyx may be necessary to achieve optimal clinical outcomes in patients with psoriasis.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065121/
[3] https://pubmed.ncbi.nlm.nih.gov/32910771/